Egyesült Államok - angol - NLM (National Library of Medicine)

stat rx usa llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide hydrochloride 5 mg - the use of metoclopramide tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets are indicated for the relief of symp

Egyesült Államok - angol - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide  tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets, usp are indicated for the relief

Egyesült Államok - angol - NLM (National Library of Medicine)

vistapharm, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg in 5 ml - the use of metoclopramide oral solution is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide oral solution is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide is indicated for the relief of sympt

Kanada - angol - Health Canada

jamp pharma corporation - metoclopramide dihydrochloride (metoclopramide hydrochloride monohydrate) - solution - 5mg - metoclopramide dihydrochloride (metoclopramide hydrochloride monohydrate) 5mg

Uganda - angol - National Drug Authority

royal pharma 2011 limited; royal pharma 2011 limited - metoclopramide hydrochloride - parenteral ordinary ampoules - 5mg/ml

Málta - angol - Medicines Authority

syri limited - metoclopramide hydrochloride - oral solution - metoclopramide hydrochloride 5 mg/5ml - drugs for functional gastrointestinal disorders

Kanada - angol - Health Canada

pharmascience inc - metoclopramide hydrochloride - solution - 5mg - metoclopramide hydrochloride 5mg - prokinetic agents

Kanada - angol - Health Canada

pharmascience inc - metoclopramide hydrochloride - solution - 5mg - metoclopramide hydrochloride 5mg - prokinetic agents

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia. control of post operative vomiting. assist in small bowel intubation.

Írország - angol - HPRA (Health Products Regulatory Authority)

ceva santé animale - metoclopramide (as hydrochloride) equivalent to metoclopramide hydrochloride ph. eur. - solution for injection - 5 mg/ml - metoclopramide - canine, feline - miscellaneous